Inhibrx Biosciences logo

Inhibrx Biosciences

INBX | NASDAQ
Chart Builder DCF Calculator
$77.66
-$5.64 (-6.77%)
At close: Nov 16, 2026, 4:00 PM ET
$77.55
-$0.11 (-0.14%)
After-hours: Nov 16, 2026, 7:32 PM ET
-6.77%

Rating

Updated: Nov 16, 2026
35.7
+5.0 pts
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #641/1021 (Top 63%)

Key Statistics

Market Data

Market Cap $1.22B
1D Range
76.50 84.59
52W Range
58.39 141.84

Valuation (TTM)

PE -8.57
PB -14.22
EV/EBITDA -8.50

Valuation (NTM)

Forward PE N/A
Forward PEG -1.50
Price Target $285.00
Loading financial charts...

Profile

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering pla...

Sector Healthcare
Industry Biotechnology
Employees 110
IPO Date May 29, 2024
Fiscal Year January - December

Latest News

Inhibrx Reports Third Quarter 2026 Financial Results

3 days ago · prnewswire.com

Inhibrx Reports Third Quarter 2026 Financial Results
Inhibrx Announces Participation in Upcoming Scientific Conferences

1 month ago · prnewswire.com

Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup

2 months ago · marketbeat.com

Inhibrx's Insider Buying Adds Fuel to a High-Short-Interest Biotech Setup
Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?

2 months ago · fool.com

Inhibrx Founder and CEO Mark Lappe Buys 25,000 Shares for $2.6 Million. What Does His Confidence Tell Investors?
Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106

2 months ago · seekingalpha.com

Inhibrx: 'Strong Buy' Maintained With Ozekibart Action Date On The Horizon And Study Win With INBRX-106
Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom

2 months ago · seekingalpha.com

Inhibrx: Market's Lukewarm Response To Yesterday's HNSCC Data Hard To Fathom
Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates

2 months ago · benzinga.com

Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates
Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study

2 months ago · reuters.com

Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

2 months ago · prnewswire.com

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
Inhibrx Reports Second Quarter 2026 Financial Results

3 months ago · prnewswire.com

Inhibrx Reports Second Quarter 2026 Financial Results

Earnings

Latest Earnings
Nov 13, 2026
EPS
-$2.46
Miss -0.54%
REV
$2M
Beat +5.26%
Next Earnings
Mar 18, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.